LXRX vs. XOMA, VNDA, VSTM, MACK, RIGL, RGLS, EBS, RZLT, OPK, and INVA
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Emergent BioSolutions (EBS), Rezolute (RZLT), OPKO Health (OPK), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
Lexicon Pharmaceuticals received 36 more outperform votes than XOMA when rated by MarketBeat users. However, 65.79% of users gave XOMA an outperform vote while only 64.66% of users gave Lexicon Pharmaceuticals an outperform vote.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 7.2% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lexicon Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 216.46%. XOMA has a consensus target price of $74.00, suggesting a potential upside of 191.22%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than XOMA.
XOMA has higher revenue and earnings than Lexicon Pharmaceuticals. XOMA is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
XOMA has a net margin of -886.91% compared to Lexicon Pharmaceuticals' net margin of -14,573.20%. XOMA's return on equity of -25.17% beat Lexicon Pharmaceuticals' return on equity.
Lexicon Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
In the previous week, XOMA had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for XOMA and 4 mentions for Lexicon Pharmaceuticals. XOMA's average media sentiment score of 0.43 beat Lexicon Pharmaceuticals' score of 0.15 indicating that XOMA is being referred to more favorably in the news media.
Summary
XOMA beats Lexicon Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
